Early Relapse for Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Therapy: A Single-center Experience

Conclusions Our results have demonstrated that ER is an important clinical indicator of patients at high risk. As applications of novel agents evolve, further studies are required to tailor therapy for this patient group. Micro-Abstract The purpose of the present study was to understand the effect of early relapse (ER) on the overall survival of myeloma patients. We analyzed the outcomes of 257 patients who had received novel agent-based induction therapy and undergone single autologous stem cell therapy at our center from 2010 to 2016. We have concluded that ER, high-risk cytogenetics, and lactate dehydrogenase > 350 UI/L are significant prognosticators for poor patient outcome in those with multiple myeloma.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research